{
    "organizations": [],
    "uuid": "1ed15db2d283c751f4f81a1ce661552b669433be",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-glaxosmithkline-says-viiv-granted/brief-glaxosmithkline-says-viiv-granted-eu-marketing-authorisation-for-juluca-idUSFWN1SS0DY",
    "ord_in_thread": 0,
    "title": "BRIEF-GlaxoSmithKline Says ViiV Granted EU Marketing Authorisation For Juluca",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 21 (Reuters) - GlaxoSmithKline PLC:\n* VIIV GRANTED EU MARKETING AUTHORISATION FOR JULUCA * VIIV HEALTHCARE RECEIVES EU MARKETING AUTHORISATION FOR JULUCA FIRST 2-DRUG REGIMEN, ONCE-DAILY, SINGLE-PILL FOR TREATMENT OF HIV Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-21T18:13:00.000+03:00",
    "crawled": "2018-05-22T19:36:26.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "glaxosmithkline",
        "plc",
        "viiv",
        "granted",
        "eu",
        "marketing",
        "authorisation",
        "juluca",
        "viiv",
        "healthcare",
        "receives",
        "eu",
        "marketing",
        "authorisation",
        "juluca",
        "first",
        "regimen",
        "treatment",
        "hiv",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}